Clinical & Mechanistic Insights From Phase 2a Studies with Optimized Consortia Therapeutic MH002 in Ulcerative Colitis & Pouchitis as Basis for Future Pipeline Development
Time: 8:30 am
day: Conference Day One
Details:
Download the Full Event Guide to see session details
